Published in:
01-12-2021 | Acute Respiratory Distress-Syndrome | Research Letter
Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic
Authors:
Christian Karagiannidis, Arthur S. Slutsky, Thomas Bein, Wolfram Windisch, Steffen Weber-Carstens, Daniel Brodie
Published in:
Critical Care
|
Issue 1/2021
Login to get access
Excerpt
Extracorporeal membrane-oxygenation (ECMO) has been widely used for COVID-19-related acute respiratory distress syndrome (ARDS), with a mortality rate of 37.1% based on the largest published series [
1]. This rate is comparable to ECMO-supported patients with non-COVID-19-related ARDS [
1]. However, some reports suggest that the real-life mortality is higher than that reported above [
2], including a cohort of 768 COVID-19 patients in Germany with an in-hospital mortality rate of 73% [
3], and a surprising finding is given that health care resources in Germany were not notably under strain during the pandemic. To better characterize this discrepancy, we evaluated in-hospital mortality for all COVID-19 patients in Germany supported with venovenous ECMO (VV-ECMO). …